Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Oral hypoglycemic agents encompass the mainstay of treatment in the majority of patients with
type 2 diabetes. Thiazolidinediones (such a pioglitazone) and Biguanides (such as metformin),
are two major groups of hypoglycemic medications that while function via different pathways,
are both effective in short- and long-term glycemic control . These medications diminish or
at least delay long term micro- and macrovascular complications associated with prolonged
insulin resistance although at different rates. The mechanisms by which this aim is achieved,
nevertheless, remains largely unclear. With adipokines playing a key role in development of
both insulin resistance and atherosclerosis, oral hypoglycemic agents might regulate these
substances by direct and indirect routes.